Induction of apoptosis by monosaccharide butyrate stable derivatives in chronic lymphocytic leukemia cells

Haematologica

Volumn 84, Issue 10, 1999, Pages 897-904

  Santini, Valeria ^a,b   Gozzini, Antonella ^a   Scappini, Barbara ^a   Caporale, Roberto ^a   Zoccolante, Antonella ^a   Rigacci, Luigi ^a   Gelardi, Elisabetta ^a   Grossi, Alberto ^a   Alterini, Renato ^a   Ferrini, Pierluigi Rossi ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Poticlinico di Careggi ^*  (Italy)

Author keywords

Apoptosis; Chronic lymphocytic leukemia; Monosaccharide butyrate derivatives

Indexed keywords

ALKYLATING AGENT; BUTANOL; BUTYRIC ACID DERIVATIVE; DNA FRAGMENT; FAS ANTIGEN; LIPOCORTIN 5; MANNOSE; MONOSACCHARIDE; PRODRUG; PROTEIN BAX; PROTEIN BCL 2; XYLITOL;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL CYCLE; CELL MEMBRANE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DNA CONTENT; DRUG STABILITY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; ONCOGENE;

AGED; ANNEXIN A5; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOOD CELLS; BUTYRATES; CELL CULTURE TECHNIQUES; CELL SIZE; DNA FRAGMENTATION; FAS LIGAND PROTEIN; FEMALE; HUMANS; INTERPHASE; KINETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MONOSACCHARIDES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 0032750354     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Keating MJ, McLaughlin P, Plunkett W, et al. Fludarabine-present status and future developments in chronic lymphocytic leukemia and lymphoma. Ann Oncol 1994; 5(Suppl 2):79-83.
2. Keating MJ, O'Brien S, Kantarjian H, et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81:2878-84.
3. O'Brien S. Clinical challenges in chronic lymphocytic leukemia. Semin Hematol 1998; 35(Suppl 3):22-6.
4. Byrd JC, Rai KR, Sausville EA, Grever MR. Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals. Semin Oncol 1998; 25:65-74.
5. Jensen M, Winkler U, Manzke O, Diehl V, Engert A. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol 1998; 77:89-91.
6. Santini V, Scappini B, Gozzini A, et al. Butyrate-stable monosaccharide derivatives induce maturation and apoptosis in human acute myeloid leukaemia cells. Br J Haematol 1998; 101:529-38.
7. Pouillart P, Douillet O, Scappini B, et al. Regioselective synthesis and biological profiling of butyric and phenylalkylcarboxylic esters derivated from D-mannose and xylitol: influence of alkyl chain length on acute toxicity. EurJ Pharm Sci 1999; 7:93-106.
8. Chang ST, Yung BY. Potentiation of sodium butyrate-induced apoptosis by vanadate in human promyelocytic leukemia cell line HL-60. Biochem Biophys Res Commu 1996; 221:594-601.
9. Cuisset L, Tichonicky L, Delpech M. A protein phosphatase is involved in the inhibition of histone deacetylation by sodium butyrate. Biochem Biophys Res Commun 1998; 246:760-4.
10. Boffa LC, Vidali G, Mann RS, Allfrey VG. Suppression of histone deacetylation in vivo and in vitro by sodium butyrate. J Biol Chem 1978; 253:3364-6.
11. Costello R, Lipcey C. Involvement of the different members of the NF-kB transcription factor family in B-chronic lymphocytic leukemia [letter; comment]. Leukemia 1993; 7:764-5.
12. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87:4990-7.
13. Pouillart P, Ronco G, Cerutti I, Trouvin JH, Pieri F, Villa P. Pharmacokinetic studies of N-butyric acid mono- and polyesters derived from monosaccharides. J Pharm Sci 1992; 81:241-4.
14. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84:1415-20.
15. Reilly JT, Nash JR, Mackie MJ, McVerry BA. Immunoenzymatic detection of fibronectin in normal and pathological haematopoietic tissue. Br J Haematol 1985; 59:497-504.
16. Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984; 32:219-29.
17. Keating MJ, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998; 92:1165-71.
18. Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998; 92:3804-16.
19. Zhang W, Ohnishi K, Shigeno K, et al. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 1998; 12:1383-91.
20. Pouillart P, Cerutti I, Ronco G, Villa P, Chany C. Butyric monosaccharide ester-induced cell differentiation and anti-tumor activity in mice. Importance of their prolonged biological effect for clinical applications in cancer therapy. Int J Cancer 1991; 49:89-95.
21. Collins RJ, Verschuer LA, Harmon BV, Prentice RL, Pope JH, Kerr JF. Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br J Haematol 1989; 71:343-50.
22. Chandra J, Niemer I, Gilbreath J, et al. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood 1998; 92:4220-9.
23. Morabito F, Filangeri M, Callea I, et al. Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs. Haematologica 1997; 82:16-20.
24. Bromidge TJ, Turner DL, Howe DJ, Johnson SA, Rule SA. In vitro chemosensitivity of chronic lymphocytic leukaemia to purine analogues-correlation with clinical course. Leukemia 1998; 12:1230-5.
25. Thomas A, El Rouby S, Reed JC, et al. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 1996; 12:1055-62.
26. Williamson KE, Kelly JD, Hamilton PW, McManus D, Johnston SR. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance [letter; comment]. Br J Cancer 1998; 78:553-4.
27. McConkey DJ, Chandra J, Wright S, et al. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol 1996; 156:2624-30.
28. Delic J, Masdehors P, Omura S, et al. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br J Cancer 1998; 77:1103-7.
29. Gaidano G, Pastore C, Capello D, Cilli V, Saglio G. Molecular pathways in low grade B-cell lymphoma. Leuk Lymphoma 1997; 26 (Suppl 1):107-13.
30. Bohmig GA, Krieger PM, Saemann MD, Wenhardt C, Pohanka E, Zlabinger GJ. n-butyrate downregulates the stimulatory function of peripheral blood-derived antigen-presenting cells: a potential mechanism for modulating T-cell responses by short-chain fatty acids. Immunology 1997; 92:234-43.
31. Morabito F, Filangeri M, Sculli G, Oliva B. In vitro modulation of bcl-2 protein expression, drug-induced apoptosis and cytotoxicity by interleukin-10 in chronic lymphocytic leukemia. Haematologica 1998; 83: 1046-8.